Literature DB >> 34679220

COVID-19 vaccination and lichen palnus.

Rujittika Mungmunpuntipantip1, Viroj Wiwanitkit2.   

Abstract

Entities:  

Year:  2021        PMID: 34679220      PMCID: PMC8661671          DOI: 10.1111/odi.14050

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   4.068


× No keyword cloud information.

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTIONS

Rujittika Mungmunpuntipantip: Conceptualization; Data curation; Formal analysis; Validation; Visualization; Writing‐original draft; Writing‐review & editing. Viroj Wiwanitkit: Conceptualization; Data curation; Supervision; Validation; Visualization.

PEER REVIEW

The peer review history for this article is available at https://publons.com/publon/10.1111/odi.14050. Dear Editor, we would like to share ideas on “Oral lichen planus following the administration of vector‐based COVID‐19 vaccine (Ad26.COV2.S) (Troeltzsch et al., 2021).” The clinical association between the immune response to vaccine and pathogenesis of lichen planus is interesting. Clinically, vaccine‐induced lichen planus is reported in some vaccinations such as hepatitis B vaccination. For COVID‐19 vaccination, it might be possible. An important possible pathogenesis of vaccine‐induced lichen planus is autoimmune development triggered by epitope. A good example of the epitope of vaccine that can trigger autoimmune is epitope S (Limas & Limas, 2002). In case that it is an abnormal immunity process or autoimmunity, an abnormal antibody specific to the vaccine epitope should be detectable (Calista & Morri, 2004). However, in the report by Troeltzsch et al. (2021), there is no data on complete work‐up for autoimmunity and antibody profile. Another possible underlying mechanism is vaccine‐associated hyperviscosity. After COVID‐19 vaccination, hyperviscosity might occur (Joob & Wiwanitkit, 2021). The mechanism of vaccine induces hyperviscosity is due to an antibody surge after vaccine administration, which results in a rapid increase of plasma concentration (Joob & Wiwanitkit, 2021). This pathological process is confirmed as a possible pathomechanism of some COVID‐19 vaccine‐related adverse effects, such as zoster‐like dermatological lesions (Mungmunpuntipantip & Wiwanitkit, 2021). In the case of the hyperviscosity problem, lichen planus is a rare but possible clinical presentation (Xiao, 1990; Xu, 1991). Xiao investigated primary contributing factors in hemorheology of oral lichen planus and identified high blood viscosity as an important factor (Xiao, 1990). Xu (1991) found that high blood viscosity results in the disturbance of microcirculation and further induced inflammation process underlying lichen planus formation. A good example is the occurrence of lichen planus in polycythemia disorder, which also has a hyperviscosity problem. Therefore, if hyperviscosity occurs after COVID‐19 vaccination, it might induce the formation of lichen planus (Oueslati et al., 2020). Again, no laboratory data are available in the report by Troeltzsch et al. (2021); hence, it is difficult to confirm that lichen planus in the case presented by Troeltzsch et al. should be due to which pathogenesis.
  8 in total

1.  [Primary investigation of multiple factors in hemorrheology of oral lichen planus].

Authors:  Y Xiao
Journal:  Zhonghua Kou Qiang Yi Xue Za Zhi       Date:  1990-09

2.  [A study on the microcirculation and hemorheology of oral lichen planus].

Authors:  Z H Xu
Journal:  Zhonghua Kou Qiang Yi Xue Za Zhi       Date:  1991-09

3.  Lichen planus in children: a possible complication of hepatitis B vaccines.

Authors:  Catherine Limas; Constantinos J Limas
Journal:  Pediatr Dermatol       Date:  2002 May-Jun       Impact factor: 1.588

4.  Oral lichen planus following the administration of vector-based COVID-19 vaccine (Ad26.COV2.S).

Authors:  Matthias Troeltzsch; Markus Gogl; Ronald Berndt; Markus Troeltzsch
Journal:  Oral Dis       Date:  2021-09-20       Impact factor: 4.068

Review 5.  Lichen planus induced by hepatitis B vaccination: a new case and review of the literature.

Authors:  Donato Calista; Massimo Morri
Journal:  Int J Dermatol       Date:  2004-08       Impact factor: 2.736

6.  Comment on: Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series.

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

7.  Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  8 in total
  2 in total

1.  Comment on "Oral lichen planus following the administration of vector based COVID-19 vaccine (Ad26.COV2.S)". Authors' reply.

Authors:  Matthias Troeltzsch; Ronald Berndt; Markus Troeltzsch
Journal:  Oral Dis       Date:  2021-10-26       Impact factor: 4.068

2.  Oral lichen planus following mRNA COVID-19 vaccination.

Authors:  Ruchadaporn Kaomongkolgit; Wanlada Sawangarun
Journal:  Oral Dis       Date:  2022-03-09       Impact factor: 4.068

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.